SuperworthRegeneron Pharmaceuticals profit margin REGN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 27.9%
- Operating margin, 12 months
- 24.7%
- Net margin on a year earlier
- −3.5 pts
- Peer median
- 22.9%
Over the twelve months to Jun 30, 2026, Regeneron Pharmaceuticals kept 27.9% of its revenue as net profit, with an operating margin of 24.7% and a gross margin of 84.9%.
Five years earlier its net margin was 50.1%.
The median for 10 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 31.4% | 24.9% | 85.4% |
| FY2024 | 31.1% | 28.1% | 86.1% |
| FY2023 | 30.1% | 30.9% | 86.2% |
| FY2022 | 35.6% | 38.9% | 87.2% |
| FY2021 | 50.2% | 55.7% | 84.8% |
| FY2020 | 41.3% | 42.1% | 86.8% |
| FY2019 | 32.3% | 33.7% | 93.0% |
| FY2018 | 36.4% | 37.8% | 93.5% |
| FY2017 | 20.4% | 35.4% | 94.5% |
| FY2016 | 18.4% | 27.4% | 96.0% |
| FY2015 | 15.5% | 30.5% | 94.1% |
| FY2014 | 12.0% | 29.2% | 95.4% |
| FY2013 | 20.2% | 36.1% | 94.4% |
| FY2012 | 54.4% | 33.2% | 93.9% |
| FY2011 | −49.7% | −46.0% | 99.1% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 27.9% | −3.5 pts | 24.7% | |
| Q1 FY26 | 29.6% | −2.3 pts | 24.3% | |
| Q4 FY25 | 31.4% | +0.3 pts | 24.9% | |
| Q3 FY25 | 32.1% | −1.5 pts | 25.9% | |
| Q2 FY25 | 31.4% | −0.7 pts | 27.0% | |
| Q1 FY25 | 31.9% | +2.5 pts | 27.2% | |
| Q4 FY24 | 31.1% | +0.9 pts | 28.1% | |
| Q3 FY24 | 33.6% | +3.1 pts | 28.7% | |
| Q2 FY24 | 32.0% | −1.9 pts | 28.9% | |
| Q1 FY24 | 29.4% | −4.4 pts | 29.4% | |
| Q4 FY23 | 30.1% | −5.5 pts | 30.9% | |
| Q3 FY23 | 30.5% | −8.7 pts | 32.2% |
Against its peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| REGNRegeneron Pharmaceuticals | 27.9% |
| VRTXVertex Pharmaceuticals | 35.0% |
| ONCBeOne Medicines | 10.7% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| UTHRUnited Therapeutics | 41.6% |
| INCYIncyte | 27.7% |
| EXELExelixis | 35.3% |
| NBIXNeurocrine Biosciences | 20.9% |
| HALOHalozyme Therapeutics | 24.9% |
| TECHBIO-TECHNE | 15.0% |
| RGENRepligen | 5.3% |
| Peer median | 22.9% |
Where Regeneron Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Regeneron Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.